Partner Jeffrey S. Grand To Speak At Fall Transvaginal Mesh Litigation Conferences

Share Article

Bernstein Liebhard LLP reports that partner Jeffrey S. Grand will be a guest speaker at two upcoming transvaginal mesh litigation conferences this fall. Recently, Mr. Grand was appointed Co-Liaison Counsel in the consolidated In re Pelvic Mesh Litigation, which is currently underway in New Jersey state court.

Bernstein Liebhard LLP is pleased to announce that partner Jeffrey S. Grand has been asked to be a guest speaker at two pelvic mesh litigation conferences this fall. The first pelvic mesh litigation conference will take place on September 14, 2011. At that conference, Mr. Grand will discuss current orders, procedures and the status of discovery in In re Pelvic Mesh Litigation (No. 006341-10 (N.J. Super. Ct.). The consolidated pelvic mesh litigation is composed of all of the transvaginal mesh lawsuits filed in New Jersey state courts. Mr. Grand’s second speaking engagement will take place on October 4, 2011. During this transvaginal mesh conference, he will share insight regarding important case intake information and discovery considerations that pelvic mesh lawyers should be cognizant of when litigating transvaginal mesh lawsuits.

Jeffrey S. Grand Previously Appointed Co-Liaison Counsel In In re Pelvic Mesh Litigation

Mr. Grand has been recognized as a leading pelvic mesh attorney. In July 2011, he was named Co-Liaison Counsel in In re Pelvic Mesh Litigation, by the Honorable Carol E. Higbee of the Superior Court of New Jersey Law Division, Atlantic County, who is overseeing the centralized management for all transvaginal mesh or pelvic mesh cases filed in New Jersey. As Co-Liaison Counsel, Mr. Grand will assist in leading the cases against C.R. Bard, Johnson & Johnson subsidiary Ethicon, and other defendants. It is expected that the number of cases filed in Atlantic County will grow significantly over the coming months.    

U.S. Food And Drug Administration Recommends Against Transvaginal Mesh

On July 13, 2011, the U.S. Food and Drug Administration (“FDA”) issued a safety communication advising patients and doctors to consider alternative treatments to transvaginal mesh. Additionally, the FDA announced that it will convene to discuss whether transvaginal mesh should be removed from the market. Further, the FDA recommended that women suffering from pelvic organ prolapse refrain from undergoing surgical placement of transvaginal mesh because the implants expose them to an increased risk of sustaining serious and fatal injuries.

In 2008, the FDA issued its first communication regarding the dangers associated with transvaginal mesh, and has since continued to review the safety of the devices. Since that time, Bernstein Liebhard LLP has provided a wealth of consumer information concerning transvaginal mesh on its website, If you or a loved one underwent a surgical procedure and have been implanted with transvaginal mesh, you may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries.

For more information about filing a transvaginal mesh lawsuit, contact an attorney at Bernstein Liebhard LLP at (877) 779-1414 or at info(at)consumerinjurylawyers(dot)com.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2011 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website